www.standoutstocks.com: Stocks That Standout For 8/20/2009 Are NVSR, BONU, CBIS, NPHC, EEGC

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com

NavStar to Reward Loyal Shareholders

ANAHEIM, CA, Aug 20, 2009 -- NavStar Technologies, Inc. (PINKSHEETS: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo, today announced that discussions are underway to consider a possible stock dividend to shareholders.

According to the company, this action is being taken to acknowledge the continued success in reaching distribution agreements with partners in Mexico, Ecuador, Japan, US and Korea and for the loyal support and patience of shareholders. The share price of the company has recently increased to reflect these achievements and plans are underway to issue a stock dividend to shareholders. The board of directors will provide an update to shareholders within days on the results of these discussions.

About NavStar Technologies, Inc.

NavStar (www.navstarinc.com) is focused on the creation of products and services that provide tracking and monitoring of vehicles and high value cargo, equipment, and other valuable and personal assets.

FORWARD-LOOKING STATEMENT This press release contains forward-looking statements within the meaning of US federal securities laws, that involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied in this press release.

BioNeutral's Consumer Grade Ygiene(TM) Delivers a 100% Total Kill on Contact of Swine Flu (H1N1) Virus - For the Home

NEWARK, N.J., Aug 20, 2009 -- BioNeutral Group, Inc. ("BioNeutral") (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia demonstrated that Ygiene(TM) Consumer Grade Antimicrobial (A significantly milder and diluted variation of the Ygiene(TM) Hospital Grade Formulation) totally eradicated the H1N1 Swine Flu Virus in 20 seconds (Virtually on Contact). This independent testing shows that Ygiene(TM) Consumer Grade Antimicrobial equaled the performance of our hospital grade formultaion and is extremely effective against the Swine Flu. It is one of a few antimicrobials actually tested against the specific H1N1 Swine Flu Virus.

Commerce Secretary Gary Locke stated, concerning the H1N1 Virus, "Its more than just a significant health issue. It has the potential to affect every aspect of our lives," Locke said. "It will take Americans from every walk of life pulling together and doing our part to mount an effective response." As the first pandemic in more than 40 years, it has the potential to cause massive disruptions for businesses, schools and governments. The United States and other northern nations have been scrambling to prepare for a resurgence of the virus The virus, which first surfaced last spring in Mexico, has spread to at least 168 countries and sickened 177,000. It has contributed to at least 1,462 deaths, including 477 in the United States, and is still circulating in the population.

"We are well on our way to achieving our objective to have the fastest acting, least expensive, longest lasting, simple to use, green formulations to eliminate swine flu from home, office, schools and public gathering places," said Dr. Andy Kielbania, chief scientist for Bioneutral Group Inc. "This mild formulation can come into daily contact with skin and clothing providing added protection against H1N1 and other dangerous organisms for the general population and the broader health care sector, as well." These independent lab test results demonstrate that BioNeutral's Ygiene(TM) Consumer Grade Antimicrobial will deliver the same speed and efficacy for eradicating the Swine Flu virus as BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial which is designed to eliminate very difficult to kill dangerous organisms in the hospital environment responsible for nosocomial infections. BioNeutral's Ygiene(TM) Consumer Grade Antimicrobial will provide household consumers the peace of mind knowing that it will be able to totally eliminate the Swine Flu virus in 20 seconds, virtually on contact, while still being environmentally friendly and gentle to surfaces being cleaned in the home. BioNeutral's Ygiene(TM) Consumer Grade Antimicrobial will contribute to maintaining good family health. This 20 second kill time is also much faster than the 10 minute kill time claimed by many of today's commercially available household disinfectants.

BioNeutral Group Inc. CEO, Stephen J. Browand, stated, "BioNeutral's Ygiene(TM) Consumer Grade Antimicrobial is an important addition to the company's growing list of formulations which will be presented to the EPA for regulatory approval." About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com About Microbiotest Inc.

Microbiotest Inc. located in Sterling Virginia is a world recognized laboratory with over 20 years of experience in testing a broad spectrum of microbiological materials. Microbiotest effectively collaborates and has an excellent track record with its clients that are developing new products to meet various Agency regulatory requirements using recognized protocols both in North America and abroad. In addition Microbiotest has the ability to design unique tests for special situations.

Forward-Looking Statements BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Cannabis Science Inc elects Ritchard L. Fishman MD to scientific advisory board

Aug 19, 2009 -- Medical marijuana research and development company Cannabis Science Inc (OTCBB:CBIS) declared on Tuesday the appointment of Dr Ritchard L. Fishman as the secondAmember of its recently formed scientific advisory board.

Fishman, a senior medical advisor, has professional affiliations with the Downey Community Hospital, Whittier Presbyterian Hospital and Whittier Hospital. He has been a guest lecturer at the Western University School of Osteopathic Medicine and Senior Medical advisor for New Life Diabetic Centers in California and Nevada.

Nutra Pharma Announces Launch of Cobroxin, an Over-the-Counter (OTC) Treatment for Stage 2 (Moderate to Severe) Chronic Pain

Nutra Pharma Has Announced the Launch of Cobroxin, an Over-the-Counter (OTC) Pain Reliever Formulated from Cobra Venom for the Treatment of Stage 2 (Moderate to Severe) Chronic Pain; Cobroxin Will Be Available in Two OTC Formulations, an Oral Spray and a Topical Gel

PLANTATION, Fla., Aug 20, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.

Additional benefits to Cobroxin include: -- All Natural -- Non-Addictive -- Non-Narcotic -- Non-Opiate -- More Potent than Morphine -- Long Lasting "Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain, and for those not receiving effective or lasting relief from OTC NSAIDs," he added.

Pain is the single most common reason patients seek medical care and accounts for half of all physician office visits in the United States. According to the American Pain Foundation, each year, more than 25 million people in the United States experience acute pain as a result of injury or surgery. Additionally, more than 50 million people in the United States are affected by ongoing chronic pain.

Current treatments for chronic pain include both opiate-based analgesics including Vicodin, Percocet, and Morphine, and those containing acetaminophen, such as Tylenol. Debate surrounding the use of opiates primarily focuses on the negative side effects observed with opiate-based analgesics, including nausea, vomiting, drowsiness, itching, constipation, respiratory depression, addiction, severe withdrawal symptoms and the buildup of tolerance, requiring higher dosage over time to experience the same effect. Additionally, recent media coverage has highlighted the dangers of using analgesics containing acetaminophen, which, in higher dosages, can cause liver damage or even death.

"What differentiates Cobroxin from other current analgesics is that it uses a novel mechanism of action discovered from cobra venom peptides for treating pain without the negative side effects observed in current opiate-based analgesics and those containing acetaminophen," explained Dr. Paul Reid, CEO of Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm. "With extensive supporting evidence from 46 human clinical studies and a well-defined safety profile, we believe that Cobroxin will soon become the preferred method for treating chronic pain," he concluded.

In preparation for commercializing Cobroxin, Nutra Pharma recently announced that ReceptoPharm had filed a patent application for a novel composition and method for oral delivery of cobra venom for the treatment of pain. The company plans to begin marketing and selling Cobroxin upon successful submission of final packaging and labeling to the FDA.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com http://www.ReceptoPharm.com http://www.Cobroxin.com SEC Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The launch of Cobroxin for the treatment of chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Empire Total Expenditure Exceeds AUD $50 Million (US $40 Million) on SEL 13/98; Registration Statement and Rights Offering to Raise AUD $11 Million (US $9 Million) Awaiting 10Q Updates and Final SEC Approval

LEAWOOD, Kan., Aug 20, 2009 -- Empire Energy Corporation International (Empire) (OTCBB:EEGC) this week cited total expenditures, meeting the license conditions, have now exceeded AUD$50 Million (US $40 Million) on SEL 13/98 and an update of the Registration Statement and Rights Offering to raise an additional AUD$11 Million (US$9 Million) is awaiting the recently filed 10Q updates and subsequent approval from the US Securities and Exchange Commission (SEC).CEO Malcolm Bendall also noted that the total expenditure, meeting the license conditions, in excess of AUD$50 Million by Empire on SEL 13/98 far exceeds all capital expenditure requirements and has met all work commitments set forth for the ten year period concerning SEL 13/98. Furthermore, he noted that exploration work and capital invested by Empire has led to the discovery of at least fifteen identifiable dome structures previously unknown before Empire's work. Additionally, these identified dome structures are believed to be capable of pooling significant commercial amounts of oil, over one billion barrels potential in the Bellevue structure alone. It is also notable that these findings have been further supported by a global independent energy research firm, RPS Energy, a leader in their field.

The process of sourcing funding is continuing and includes the potential fifty million dollar line of credit facility extended to Mr. Bendall, announced in the press release, on June 12, 2009. In this same press release Mr. Bendall has stated he 'intends to use the proceeds of this financing to take down his Rights in the Rights Offering currently under review by the United States Securities and Exchange Commission (www.sec.gov) followed by taking down his over allotment option to the extent that other Rights Holders fail to exercise.' The rights offering will provide a regulated environment which gives all shareholders equal opportunity to participate in the future of the company and is expected to be fully subscribed. The Rights Offering will proceed upon completion of the registration statement and approval by the SEC. If fully subscribed, the rights offering would raise AUD$11 Million (US$9 Million) for our drilling program and should enable us to drill the Bellevue and Thunderbolt sites.

Empire continues to talk with drilling company Hunt Energy about its ongoing operations regarding the drilling program and other issues. The Hunt rig remains stacked in Launceston, Tasmania, Australia and is available to remobilize to the Bellevue site as soon as funding is available.

As an additional matter, Mr. Bendall has offered, after long and careful consideration, to bring into Empire the North and South American rights for a very significant proprietary technology that is expected to significantly address and impact a critical element of the energy industry globally. This technology involves high percentage recovery of flare gas as liquid fuel which would otherwise be burned off into the environment. This flare gas burn-off represents a huge loss in usable fuel and takes place at well heads and refineries worldwide. Valuation, validation, commercialization and implementation are now being quantified by an outside party to set commercial terms for the transaction. Results contained in this report are expected to be quite substantial on an annualized basis. This is a very significant and positive development for Empire and is expected to significantly impact the bottom line and future potential growth. We estimate North and South America currently flare in excess of 6 Billion cubic meters of gas per annum, however, due to local, regional and global politically sensitive impacts, these figures are hard to substantiate and will be the subject of further considerable investigation. We estimate if this was converted into liquid, this would represent in excess of US$2 Billion worth of usable liquid fuel per annum.

Mr. Bendall will be posting shortly on the Empire's web site a letter to Empire shareholders discussing, in more detail, SEL 13/98 and other positive developments. We encourage all our shareholders to visit our company website at www.empireenergy.com and read Mr. Bendall's letter.

Empire Energy Corporation is an international oil and gas exploration company, focusing on developing assets in one of the world's last virgin basins and to become a leading low-cost finder of hydrocarbons. The Company is currently operating in Tasmania's central and northern basins.

This press release contains forward-looking statements based on our current expectations about our company and our industry. You can identify these forward-looking statements when you see us using the words such as "expect," "anticipate," "estimate," "believes," "plans" and other similar expressions. These forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of our ability to complete required financings and other preconditions to the completion of the transactions described herein and Empire's ability to successfully acquire reserves and produce its resources among other issues. We undertake no obligation to publicly update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. We caution you not to place undue reliance on those statements. For a more detailed discussion of risks and other factors related to Empire Energy Corporation International, please refer to 10-K and 10 Q reports filed with the U.S. Securities and Exchange Commission.

About Standoutstocks.com

www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: mailto:info@standoutstocks.com

CONTACT: Jason A. Hilton, Standout Stocks
Tel: +1 585 729 8809
e-mail: Jason@Newmediaadvisorsllc.com
e-mail: mailto:info@standoutstocks.com
WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (EEGC) EEGC. (EEGC) has Short Term PowerRatings at TradingMarkets. Details on (EEGC) Short Term PowerRatings is available at This Link.

For full details on (NPHC) NPHC. (NPHC) has Short Term PowerRatings at TradingMarkets. Details on (NPHC) Short Term PowerRatings is available at This Link.

For full details on (BONU) BONU. (BONU) has Short Term PowerRatings at TradingMarkets. Details on (BONU) Short Term PowerRatings is available at This Link.

For full details on (NVSR) NVSR. (NVSR) has Short Term PowerRatings at TradingMarkets. Details on (NVSR) Short Term PowerRatings is available at This Link.

For full details on (CBIS) CBIS. (CBIS) has Short Term PowerRatings at TradingMarkets. Details on (CBIS) Short Term PowerRatings is available at This Link.

For full details on (BONUE) BONUE. (BONUE) has Short Term PowerRatings at TradingMarkets. Details on (BONUE) Short Term PowerRatings is available at This Link.